Recent Advances in IgA Nephropathy: Key Updates for PLAB 2 Candidates

Introduction

IgA Nephropathy (IgAN), also known as Berger's disease, remains one of the most common primary glomerulonephritis worldwide. As medical professionals preparing for PLAB 2, staying updated with the latest advances in diagnosis and management is crucial. This article covers the most recent developments in IgA Nephropathy that are high-yield for your exam.

Epidemiology and Pathogenesis Updates

IgA Nephropathy is characterized by deposition of galactose-deficient IgA1 antibodies in the mesangium. Recent research has significantly improved our understanding of the disease mechanisms:

• Genetic Insights: Genome-wide association studies (GWAS) have identified multiple susceptibility loci, including variants in genes involved in mucosal immunity and complement regulation

• Environmental Factors: New evidence links gut dysbiosis and mucosal infections to disease progression

• Autoantibodies: The role of IgG and IgA autoantibodies againstGd-IgA1 has been further characterized

2024-2025 Guideline Updates

KDIGO 2024 Guidelines

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have been updated with significant changes:

1. Risk Stratification:

   • Introduction of the International Risk Prediction Tool (INRPT) incorporating clinical and histological factors

   • Proteinuria threshold reduced to <0.5g/day as the target for treatment response

2. First-Line Therapy:

   • Optimized supportive care remains the foundation

   • Corticosteroids now have more specific indications - recommended for patients at high risk of progression despite 90 days of optimized supportive care

3. Targeted Therapies:

   • SGLT2 Inhibitors: Now recommended for patients with eGFR >20ml/min/1.73m² and proteinuria >0.5g/day, regardless of diabetes status (based on DAPA-CKD and EMPA-KIDNEY trials)

   • Corticosteroids: Updated dosing regimens with risk mitigation strategies for diabetes and obesity

Novel Therapeutic Agents

Agents Receiving Recent Attention

1. B-cell Activating Factor (BAFF) Inhibitors:

   • Belimumab showing promise in phase II trials

   • Potential role in reducing autoantibody production

2. Complement Inhibitors:

   • Iptacopan (Factor B inhibitor) - positive results in phase II

   • Avacopan (C5a receptor antagonist) - being studied in IgAN

3. Endothelin Receptor Antagonists:

   • Sparsentan (dual ETA/AT1 antagonist) - approved in 2023, showing significant proteinuria reduction

4. Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Inhibitors:

   • Ongoing trials targeting gut mucosal immunity

Diagnostic Advances

Biomarkers

• Galactose-deficient IgA1 (Gd-IgA1): Serum levels now measurable commercially

• Uromodulin: Emerging as a biomarker for kidney function and disease progression

• Soluble BAFF (sBAFF): Correlates with disease activity

Histopathology

• MEST-C Score: Continues to be validated with new data on prognostic significance

• Oxford Classification Update (2023):

  • Additional segmental sclerosis (S1) now includes scoring of percentage involvement

  • New emphasis on crescentic disease patterns

Management Algorithm for PLAB 2

Step 1: Assess Risk

• Proteinuria >1g/day despite 3 months of optimized supportive care = high risk

• eGFR <50ml/min/1.73m² = high risk

• histological evidence of active disease (crescents, inflammation)

Step 2: Optimize Supportive Care

• Blood Pressure Control: Target <130/80mmHg with ACEi/ARB (maximum tolerated dose)

• SGLT2 Inhibitors: Add if eGFR >20ml/min/1.73m²

• Sodium restriction: <2g/day

• Weight optimization

• Smoking cessation

Step 3: Consider Immunosuppression

• Corticosteroids for high-risk patients without contraindications

• Consider adding mycophenolate mofetil in specific populations

Prognosis Updates

Recent longitudinal studies show:

• 30% of patients develop kidney failure within 20 years

• Earlier treatment initiation correlates with better outcomes

• SGLT2 inhibitors have changed the natural history of the disease

• Crescentic IgAN still carries poor prognosis but responds to aggressive immunosuppression

Key Takeaways for PLAB 2

1. SGLT2 inhibitors are now first-line alongside ACEi/ARB for proteinuric IgAN

2. Corticosteroids have more restricted indications - high-risk patients only

3. New targeted therapies like sparsentan are changing treatment landscape

4. Risk stratification is crucial - use the International Risk Prediction Tool

5. Crescents indicate aggressive disease requiring prompt treatment

6. Supportive care optimization remains fundamental before escalation

Conclusion

The management of IgA Nephropathy has evolved significantly with the introduction of SGLT2 inhibitors and newer targeted therapies. For PLAB 2 candidates, understanding these updates is essential as they represent the current standard of care. Remember to apply a risk-stratified approach and always optimize supportive care before considering escalation therapy.

Stay tuned for more updates on renal medicine and other specialties for your PLAB 2 preparation!